The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Danchenko I.Y.

Vagner Perm State Medical University

Baidina T.V.

Vagner Perm State Medical University

Kuklina E.M.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Trushnikova T.N.

Wagner Perm State Medical University

Nekrasova I.V.

Institute of Ecology and Genetics of Microorganisms — Ural Branch of the Russian Academy of Sciences

Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example of molecules Sema4D and CD72

Authors:

Danchenko I.Y., Baidina T.V., Kuklina E.M., Trushnikova T.N., Nekrasova I.V.

More about the authors

Read: 2363 times


To cite this article:

Danchenko IY, Baidina TV, Kuklina EM, Trushnikova TN, Nekrasova IV. Relapsing-remitting multiple sclerosis: clinical and immunological aspects of the pathology on the example of molecules Sema4D and CD72. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(7‑2):75‑81. (In Russ.)
https://doi.org/10.17116/jnevro202112107275

Recommended articles:
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
Biomarkers in tear fluid in uveitis. Russian Annals of Ophthalmology. 2025;(4):88-95

References:

  1. Boiko AN, Boiko OV, Gusev EI. The choice of the optimal drug for pathogenic treatment of multiple sclerosis: a current state of the problem (a review). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114:10(2):77-91. (In Russ.). https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2/2014/10/downloads/ru/031997-729820141040
  2. Stolyarov ID. The modern methods of diagnostics and treatment of multiple sclerosis. Vestnik Roszdravnadzora. 2010;4:64-67. (In Russ.). https://elibrary.ru/download/elibrary_15195667_39522683.pdf
  3. Karakulova YuV, Zhelnin AV, Trushnikova TN. Epidemiology and geography of multiple sclerosis in the Perm region. Vestnik Roszdravnadzora. 2013;2:43-45. (In Russ.).
  4. Chapoval SP, Vadasz Z, Chapoval AI, Toubi E. Semaphorins 4A and 4D in chronic inflammatory diseases. Inflamm Res. 2017;66:111-117.  https://doi.org/10.1007/s00011-016-0983-5
  5. Kumanogoh A, Marukawa S, Suzuki K, et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature. 2002;419(6907):629-633.  https://doi.org/10.1038/nature01037
  6. Koda T, Okuno T, Takata K, et al. Sema4A inhibits the therapeutic effect of IFN-β in EAE. J Neuroimmunol. 2014;268(1-2):43-49.  https://doi.org/10.1016/j.jneuroim.2013.12.014
  7. De Wit J. Role of semaphorins in the adult nervous system. Prog Neurobiol. 2003;71(2-3):249-267.  https://doi.org/10.1016/j.pneurobio.2003.06.001
  8. Hsieh HH, Chang WT, Yu L, Rao Y. Control of axon-axon attraction by Semaphorin reverse signaling. Proc Natl Acad Sci USA. 2014;111(31):11383-11388. https://doi.org/10.1073/pnas.1321433111
  9. Zhang Y, Liu B, Ma Y, Jin B. Sema 4D/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol. 2013;10(2):97-98.  https://doi.org/10.1038/cmi.2012.65
  10. Kumanogoh A, Suzuki K, Ch’ng E, et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J Immunol. 2002;169(3):1175-1181. https://doi.org/10.4049/jimmunol.169.3.1175
  11. Giraudon P, Vincent P, Vuaillat C, et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J Immunol. 2004;172(2):1246-1255. https://doi.org/10.4049/jimmunol.172.2.1246
  12. Wang X, Kumanogoh A, Watanabe C, et al. Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses. Blood. 2001;97(11):3498-3504. https://doi.org/10.1182/blood.v97.11.3498
  13. Kumanogoh A, Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001;22(12):670-676.  https://doi.org/10.1016/s1471-4906(01)02087-7
  14. Tamagnone L, Artigiani S, Chen H, et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell. 1999;99(1):71-80.  https://doi.org/10.1016/s0092-8674(01)00216-1
  15. Kumanogoh A, Watanabe C, Lee I, et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity. 2000;13(5):621-631.  https://doi.org/10.1016/s1074-7613(00)00062-5
  16. Braley TJ, Segal BM. B-cell Targeting Agents in the Treatment of Multiple Sclerosis. Current Treatment Options in Neurology. 2013;15(3):259-269.  https://doi.org/10.1007/s11940-013-0232-y
  17. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.  https://onlinelibrary.wiley.com/doi/full/10.1002/ana.22366
  18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;6(4):907-911.  https://doi.org/10.1212/wnl.46.4.907
  19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. https://doi.org/10.1212/wnl.33.11.1444
  20. Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. Eur J Neurol. 2000;7(3):281-289.  https://doi.org/10.1016/s0165-5728(98)91768-4
  21. Baidina TV, Kuklina EM, Trushnikova TN, et al. Pathogenetic and clinical peculiarities of disseminated sclerosis. Perm Medical Journal. 2016;33(4):17-22. (In Russ.).
  22. Kuklina EM, Baidina TV, Danchenko IY, Nekrasova IV. Semaforin Sema4D in the immune system in multiple sclerosis. Bulletin of Experimental Biology and Medicine (English version). 2014;157(2):234-237. (In Russ.). https://doi.org/10.1007/s10517-014-2533-x
  23. Adachi T, Flaswinkel H, Yakura H, et al. The B cell surface protein CD72 recruits the tyrosine phosphatase SHP-1 upon tyrosine phosphorylation. J Immunol. 1998;160(10):4662-4665. https://doi.org/10.1016/s0165-5728(98)91768-4
  24. Kumanogoh A, Kikutani H. Biological functions and signaling of a transmembrane semaphorin, CD100/Sema4D. Cell Mol Life Sci. 2004;61(3):292-300.  https://doi.org/10.1007/s00018-003-3257-7

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.